This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Agenus' CEO Discusses Q2 2011 Results - Earnings Call Transcript

Garo Armen

Thank you, Shalini. I would like to begin this call by highlighting the fact that many of the clinical programs that have been under development for several years by us and by our partners are making significant progress and continue to mature.

This is a very exciting time for the company as we could hit as many as eight upcoming milestone events reported in the second half of this year through 2012 and all of which obviously could be great value to us and to our shareholders.

We are excited to be participating in the advancing Immunotherapy field with several steps the potential success in many vaccine candidates utilizing our platform and technology in the advantage of clinics and several are getting very close to potential commercialization.

It is important also note that beyond our saponin platform of QS-21 Stimulon adjuvant and our recombinant common series platform, which is represented with HerpV for the treatment of genital herpes. Agenus is well-positioned with its Prophage series of vaccines prevent it from recent advances in the field of cancer immunology and cancer vaccines.

The FDA approval for Prophage and ponezumab which represents very important immune system modifying drugs, validate the fact that in addition to preventing disease, immune based drugs can be successfully used in the treatment of cancer.

To start, I would like to now give you a brief overview of QS-21 Stimulon adjuvant, which is a part of our saponin platform. Adjuvants are an essential part of an effective vaccine as it enhance the ability of a vaccine to elicit strong and durable immune responses.

Key licensees of QS-21 include GlaxoSmithKline and JANSSEN Alzheimer Immunotherapy, which is a division of J&J. The programs under development by our partners are advancing and data from Phase 3 clinical trials of three vaccine candidates for malaria and [MAGE IIIA] in non-small cell lung cancer and melanoma are anticipated to be released in the second half of this year, as well as during 2012. A Phase 3 vaccine program for shingles continues to rapidly advance in the clinic.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,135.72 +38.82 0.21%
S&P 500 2,101.04 +2.51 0.12%
NASDAQ 4,982.8090 +15.6680 0.32%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs